Download full announcement Demonstrates ability to predict early rejection in kidney transplant Supports successful development of a predictive blood test for transplant patients Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease,
Download full announcement High quality production-scale batches of critical materials successfully produced Key milestone achieved for scaled commercial test production Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces
Download full announcement Renalytix AI plc(AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that the New York State Department of Health has issued a Clinical Laboratory Improvement Amendment (CLIA) 1 certificate under the Centers for
Download full announcement Investigators now include transplant experts from University of Oxford, Yale School of Medicine, Emory University School of Medicine, Icahn School of Medicine at Mount Sinai, University of Manitoba, Westmead Hospital Sydney, University of Alabama at Birmingham, and
Download full announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces a collaboration with University Medical Center Groningen (UMCG), Netherlands, to evaluate KidneyIntelX™ across over 3,500 patients with Type
Download full announcement Provides priority regulatory review of AI-enabled diagnostic for fast-progressing kidney disease Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that it has been granted Breakthrough Device
Download full announcement The Company was informed that today, Christopher Mills, a non-executive director, completed the purchase of 3,168 ordinary shares of 0.25 pence each (“Ordinary Shares”) in the Company at a price of 112 pence per share. Following this purchase, Mr Mills is interested in
Download full announcement EKF Diagnostics Holdings (AIM: EKF), the AIM quoted point-of-care business, notes the announcement by Renalytix AI plc (AIM: RENX) (“RenalytixAI”), that on 26 April 2019 EKF Diagnostics plc (“EKF”) acquired 100,074 ordinary RenalytixAI shares of £0.0025 each.
Download full announcement NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Renalytix AI Plc 1b.
Download full announcement RenalytixAI machine learning approach outperformed current standard of care in 1,369 patient study Renalytix AI plc(AIM: RENX), the developer of artificial intelligence-enabled diagnostics for kidney disease, announces publication of results generated by a confirmation
